Inventory - Provention Bio Inc (F:2VB)

Watchlist Manager

Watchlist

Price: 21.6 EUR -0.46%

Market Cap: €2B

Provention Bio Inc
Inventory

Quarterly

Annual

Adjust for Inflation

Balance Sheet

Provention Bio Inc
Inventory Peer Comparison

Company		Inventory	CAGR 3Y	CAGR 5Y	CAGR 10Y
P	Provention Bio Inc F:2VB	Inventory $1.2m	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
	Johnson & Johnson NYSE:JNJ	Inventory $14.1B	CAGR 3-Years 4%	CAGR 5-Years 9%	CAGR 10-Years 6%
	Bristol-Myers Squibb Co NYSE:BMY	Inventory $2.8B	CAGR 3-Years 10%	CAGR 5-Years 7%	CAGR 10-Years 9%
	Pfizer Inc NYSE:PFE	Inventory $11.5B	CAGR 3-Years 6%	CAGR 5-Years 4%	CAGR 10-Years 4%
	Merck & Co Inc NYSE:MRK	Inventory $6.4B	CAGR 3-Years 5%	CAGR 5-Years 1%	CAGR 10-Years 2%
	Eli Lilly and Co NYSE:LLY	Inventory $12.2B	CAGR 3-Years 47%	CAGR 5-Years 28%	CAGR 10-Years 14%

Provention Bio Inc
Glance View

Market Cap

2B EUR

Industry

Pharmaceuticals

Provention Bio Inc., a biopharmaceutical entity, emerged with a focused mission: pioneering the interception and prevention of immune-mediated diseases. The company identified a niche in the therapeutic landscape by addressing the root causes rather than merely managing symptoms. At its core, Provention Bio aimed to delay or halt the progression of autoimmune disorders, particularly Type 1 Diabetes (T1D), by leveraging immunotherapy. Their flagship product, teplizumab, stood as a testament to this strategy. This monoclonal antibody was designed to slow down the progression of T1D by modifying the immune system's response, thereby extending the period before insulin dependence begins in at-risk individuals. Rather than following the conventional path of reacting to fully manifested diseases, Provention Bio championed a proactive approach, capitalizing on early intervention. Financially, Provention Bio's business model revolved around developing and commercializing their innovative therapies, steering through regulatory approvals, and forming strategic partnerships. The company secured collaborations with larger pharmaceutical firms, like Sanofi, not only to bolster financial resources required for large-scale drug trials but also to leverage distribution channels once the therapies hit the market. Revenue streams were projected from licensing agreements, milestone payments, and, eventually, product sales upon successful commercialization. By addressing a significant unmet medical need, Provention Bio positioned itself to capitalize on the growing interest in disease prevention, while also offering hope to patients facing the realities of living with autoimmune diseases.

View 2VB Analysis

2VB Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

Provention Bio Inc
F:2VB

Provention Bio Inc
Inventory

Provention Bio Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Provention Bio Inc
Glance View

See Also

What is Provention Bio Inc's Inventory?

Inventory
1.2m USD

Company

Help

Tools

Stocks

52 Week Range	N/A N/A
Price Target

Provention Bio Inc F:2VB

Provention Bio Inc Inventory

Provention Bio Inc Inventory Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

Provention Bio Inc Glance View

See Also

What is Provention Bio Inc's Inventory? Inventory 1.2m USD

Company

Help

Tools

Stocks

Provention Bio Inc
F:2VB

Provention Bio Inc
Inventory

Provention Bio Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Provention Bio Inc
Glance View

What is Provention Bio Inc's Inventory?

Inventory
1.2m USD